The board of directors of Zensun Enterprises Limited announced that Dr. Liu Qiao ("Dr. Liu") has resigned as an independent non-executive Director of the Company with effect from 18 October 2021 in order to devote more time to his other business commitments. Dr. Liu has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the "Stock Exchange"). The Board would like to express its gratitude and appreciation to Dr. Liu for his valuable contribution to the Company during his tenure of service. The Board announced that Dr. Li Huiqun has been appointed as an independent non-executive Director with effect from 18 October 2021. Dr. Li, aged 55, obtained a bachelor's degree in economics, a master's degree in economics and a doctorate degree in economics from the School of Economics of Wuhan University, Hubei Province, China in 1988, 1991 and 1994, respectively. Dr. Li has extensive experience in the banking and financial markets sector. From April 1994 to October 2015, she served as head of several divisions and on vice-president level positions in the Shenzhen Central Branch of the People's Bank of China, in charge of the Money and Credit Division, the Financial Research Office, the Bullion Management Division, labor union work and management of human resources. From November 2015 to June 2021, she has been the vice president of Shenzhen Rural Commercial Bank in charge of asset management, financial market and inter-bank business and management of the Qianhai branch. Dr. Li will hold office until the first annual general meeting after her appointment and be subject to re-election at such meeting; and thereafter will be subject to retirement by rotation and re- election at the Company's annual general meeting in accordance with the articles of association of the Company. A service contract has been entered into between the Company and Dr. Li for a term of three years with effect from 18 October 2021. Pursuant to the service contract, Dr. Li is entitled to a director's fee of HKD 240,000 per annum, which will be reviewed by the Board from time to time based on the recommendation of the renumeration committee of the Company with reference to directors' fees paid by comparable companies, time commitment, duties and responsibilities of Dr. Li. Dr. Li has confirmed that she meets the independence criteria as set out in Rule 3.13 of the Rules Governing the Listing of Securities on the Stock Exchange.